retatrutide triple agonist gip glp-1 glucagon receptor Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide | GLP-1R/GIPR/GCGR ligand |

Syringes should be loaded immediately before injection rather than pre-filled and stored

This refers to any mole or spot that stands out or looks different from other moles on the body

C57BL/6J mice were housed at 27C in a controlled environment with a 12-h/12-h light/dark cycle, with free access to water and a high-cholesterol diet (HCD

If you have questions about BPC-157 or any emerging therapy, Southern Care Anesthetics is dedicated to providing clear, evidence-based guidance

This infusion is not a treatment for any medical condition, and there is currently limited scientific evidence for cosmetic or general-wellness benefits from IV antioxidant infusions